Literature DB >> 7624117

Activated RET/PTC oncogene elicits immediate early and delayed response genes in PC12 cells.

D Califano1, C Monaco, G de Vita, A D'Alessio, N A Dathan, R Possenti, G Vecchio, A Fusco, M Santoro, V de Franciscis.   

Abstract

The expression of the receptor-like tyrosine kinase RET is associated with tumors, tissues or cell lines of neural crest origin. In addition RET products (Ret) are involved in determining cell fate during the differentiation of the enteric nervous system and during renal organogenesis. However, as yet, no direct evidence exists to indicate that the Ret kinase activity might interfere in a specific way with cellular differentiation, or proliferation, of a neural crest derived cell line. By using two constitutively activated forms of RET (RET/PTC1 and RET/PTC3) in transient transfection experiments, we have obtained evidence that active RET could reprogramme the gene expression pattern in the rat pheochromocytoma PC12 cell line. Transcription driven by gene promoters, such as NGFI-A and vgf, which belong, respectively, to primary and delayed response genes to nerve growth factor (NGF), and by the neuron-specific enolase (NSE) promoter, is rapidly induced by the expression of activated RET oncogenes. This induction is not elicited in other non neural derived cell types tested. We also demonstrate that endogenous ras activity is required for RET induction of these neural markers. Finally, in the RET/PTC transfected PC12 cells, NGF is unable to induce further their transcription. This suggests that RET/PTC could share an intracellular signalling pathway with the NGF-receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7624117

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  5 in total

1.  Molecular heterogeneity of RET loss of function in Hirschsprung's disease.

Authors:  F Carlomagno; G De Vita; M T Berlingieri; V de Franciscis; R M Melillo; V Colantuoni; M H Kraus; P P Di Fiore; A Fusco; M Santoro
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

2.  A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells.

Authors:  D Califano; A D'Alessio; G L Colucci-D'Amato; G De Vita; C Monaco; G Santelli; P P Di Fiore; G Vecchio; A Fusco; M Santoro; V de Franciscis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 3.  Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.

Authors:  J R Hansford; L M Mulligan
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

4.  Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure.

Authors:  A H Fischer; J A Bond; P Taysavang; O E Battles; D Wynford-Thomas
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

5.  Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.

Authors:  Alex Cazes; Lucille Lopez-Delisle; Konstantina Tsarovina; Cécile Pierre-Eugène; Katleen De Preter; Michel Peuchmaur; André Nicolas; Claire Provost; Caroline Louis-Brennetot; Romain Daveau; Candy Kumps; Ilaria Cascone; Gudrun Schleiermacher; Aurélie Prignon; Frank Speleman; Hermann Rohrer; Olivier Delattre; Isabelle Janoueix-Lerosey
Journal:  Oncotarget       Date:  2014-05-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.